Heparin in acute stroke with atrial fibrillation: Clinical relevance of very early treatment

Archives of Neurology

Volumn 56, Issue 9, 1999, Pages 1098-1102

  Chamorro, Angel ^a,b   Vila, Nicolas ^a   Ascaso, Carlos ^b   Blanc, Rosa ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; THROMBOPLASTIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BRAIN HEMORRHAGE; BRAIN INFARCTION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE SEVERITY; FUNCTIONAL ASSESSMENT; HEART ATRIUM FIBRILLATION; HEPARINIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RECURRENT DISEASE; STROKE; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0032888360     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.56.9.1098     Document Type: Article

References (31)

1. Babikian VL, Kase C, Pessin MS, Norrving B, Gorelick PB. Intracerebral hemorrhage in stroke patients anticoagulated with heparin. Stroke. 1989;20:1500-1503.
2. Chamorro A. Anticoagulation and antiaggregation for acute cerebral ischemia. In: Castillo J, Dávalos A. Toni D, eds. Management of Acute Ischemic Stroke. Barcelona, Spain: Springer-Verlag Ibérica; 1997:97-108.
3. Mohr JP, Albers GW, Amarenco P, et al. Etiology of stroke. Stroke. 1997;28: 1506-1510.
4. Chamorro A, Vila N, Saiz A, Alday M, Tolosa E. Safety of heparin in acute ischemic stroke. Neurology. 1996;46:589-590.
5. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomized trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet. 1997;349:1569-1581.
6. Chamorro A, Vila N, Saiz A, Alday M, Tolosa E. Early anticoagulation after large cerebral infarction: a safety study. Neurology. 1995;45:861-865.
7. Abbate R, Gori AM, Modesti PA, et al. Heparin, monocytes, and procoagulant activity. Haemostasis. 1990;1:98-100.
8. Sahu A, Pangburn MK. Identification of multiple sites of interaction between heparin and the complement system. Mol Immunol. 1993;30:679-684.
9. Nelson RM, Cecconi O, Roberts WG, Aruffo A, Lindhart RJ, Bevilacqua MP. Heparin oligosaccharides bind L-and P-selectin and inhibit acute inflammation. Blood 1993;82:3253-3258.
10. Hopåsen AKM, Abrahamsen TG. Heparin suppresses lipopolysaccharide-induced monocyte production of several cytokines, but simultaneously stimulates C3 production. Thromb Res. 1995;80:179-184.
11. Mathew NT, Meyer JS, Rivera VM, Charney JZ, Hartmann A. Double-blind evaluation of glycerol therapy in acute cerebral infarction. Lancet. 1972;2:1327-1329.
12. Aboaf AP, Wolf PS. Paroxysmal atrial fibrillation: a common but neglected entity. Arch Intern Med. 1996;156:362-367.
13. Salzman EW, Rosenberg RD, Smith MH, Lincoln JN, Favreau L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest. 1980;65:54-73.
14. Cabin HS, Clubb KS, Perlmutter RA, Feinstein AR. Risk for systemic embolization of atrial fibrillation without mitral stenosis. Am J Cardiol. 1990;65:1112-1116.
15. Dávalos A, Castillo J, Martinez-Vila E, for the Cerebrovascular Diseases Study Group of the Spanish Society of Neurology. Delay in neurological attention and stroke outcome. Stroke. 1995;26:2233-2237.
16. Langhorne P, Williams BO, Gilchrist W, Howie K. Do stroke units save lives? Lancet. 1993;342:395-398.
17. Toni D, Fiorelli M, Bastianello S, et al. Acute ischemic strokes improving during the first 48 hours of onset: predictability, outcome, and possible mechanisms: a comparison with early deteriorating strokes. Stroke. 1997;22:10-14.
18. Alberts MJ, Dawson DV, Massey EW. A follow-up survey of clinical practices for the use of heparin, warfarin, and aspirin. Neurology. 1994;44:618-621.
19. Cerebral Embolism Study Group. Immediate anticoagulation of embolic stroke: a randomized trial. Stroke. 1983;14:668-676.
20. Bousser MG. Aspirin or heparin immediately after stroke? Lancet. 1997;349: 1564-1565.
21. Sacco RL, Foulkes MA, Mohr JP, Wolf PA, Hier DB, Price TR. Determinants of early recurrence of cerebral infarction: the stroke databank. Stroke. 1989;20: 983-989.
22. Dupas JL, Brazier F, Yzet T, Roussel B, Duchmann JC. Treatment of active Crohn's disease with heparin [abstract]. Gastroenterology. 1997;11:A900.
23. Brazier F, Yzet T, Boruchowicz A, Colombel JF, Duchmann JC. Treatment of ulcerative colitis with heparin [abstract]. Gastroenterology. 1997;11:A872.
24. Yanaka K, Spellman SR, McCarthy JB, Oegema TR, Low WC, Camarata PJ. Reduction of brain injury using heparin to inhibit leukocyte accumulation in a rat model of transient focal cerebral ischemia. J Neurosurg. 1996;85:1102-1207.
25. Kochanek PM, Hallenbeck JM. Polymorphonuclear leukocytes and monocytes/ macrophages in the pathogenesis of cerebral ischemia and stroke. Stroke. 1992; 23:1367-1379.
26. Feuerstein GZ, Wang X, Yue T, Barone FC. Inflammatory cytokines and stroke: emerging new strategies for stroke therapeutics. In: Moskowith MA, Caplan LR, eds. Cerebrovascular Diseases. Newton, Mass: Butterworth-Heinemann; 1995: 75-91.
27. Tangelder GJ, Arfors KE. Inhibition of leukocyte rolling in venules by protamine and sulfated polysaccharides. Blood. 1991;77:1565-1571.
28. Ley K, Cerrito M, Arfors KE. Sulfated polysaccharides inhibit rolling in rabbit mesentery venules. Am J Physiol. 1991;260:H1667-H1673.
29. Diamond MS, Alon R, Parkos CA, Quinn MT, Springer TA. Heparin is an adhesive ligand for the leukocyte integrin Mac-1 (CD11b/CD18). J Cell Biol. 1995; 130:1473-1482.
30. Bevilacqua M, Nelson RM, Mannori G, Cecconi O. Endothelial-leukocyle adhesion molecules in human disease. Annu Rev Med. 1994;45:361-378.
31. Major ongoing stroke trials. Stroke. 1997;28:475-479.